The global Schmallenberg Virus Treatment market size was valued at US$ 110 million in 2023 and is expected to reach US$ 193.8 million by 2030, grow at a compound annual growth rate (CAGR) of 8.4% from 2023 to 2030
Schmallenberg Virus (SBV) is a viral disease that primarily affects ruminant animals, including cattle, sheep, and goats. The virus was first identified in Europe in 2011 and has since spread to different regions globally. However, there were no specific antiviral treatments or vaccines approved for Schmallenberg Virus in animals at that time.
Treatment options for Schmallenberg Virus mainly focused on supportive care and management of symptoms to improve the animals' overall health and minimize the impact of the disease. These included providing pain relief, anti-inflammatory medications, and ensuring proper nutrition and hydration. Preventive measures, such as vector control and vaccination strategies, were also essential in minimizing the spread of the virus.
Schmallenberg Virus Treatment Market Regional Insights
- Europe is the leading region in the Schmallenberg virus treatment market, accounting for a share of over 50% in 2022. This is due to the high prevalence of SBV in Europe, as well as the strong demand for vaccines from livestock farmers. The European Commission has approved two vaccines for SBV, and these are widely used in the region.
- North America is the second-largest region in the market, with a share of over 25% in 2022. The United States is the largest market in North America, followed by Canada. The demand for vaccines in North America is driven by the high number of livestock farms in the region.
- Asia Pacific is the third-largest region in the market, with a share of over 15% in 2022. China is the largest market in Asia-Pacific, followed by India. The demand for vaccines in Asia-Pacific is driven by the growing livestock population in the region.
Figure 1. Global Schmallenberg Virus Treatment Market Share (%), by Region, 2023
Schmallenberg Virus Treatment Market Drivers:
- Emerging Outbreaks: The occurrence of new outbreaks of Schmallenberg Virus in different regions drives the need for effective treatment options. As the virus spreads to new areas and affects more livestock, there is an increasing demand for treatments to mitigate the impact of the disease on animal health and productivity.
- Growing Awareness: With increased awareness of the Schmallenberg Virus and its potential effects on ruminant populations, veterinarians, livestock farmers, and animal health authorities seek effective treatment strategies. As stakeholders become more knowledgeable about the virus, they are likely to actively seek and adopt available treatment options.
- Research and Development: Ongoing research and development efforts by veterinary pharmaceutical companies and academic institutions play a vital role in driving the Schmallenberg Virus treatment market. Continuous research aims to identify antiviral drugs, vaccines, and supportive care measures to improve animal health outcomes.
- Supportive Measures: While there may not be specific antiviral treatments for Schmallenberg Virus, supportive measures, such as pain relief and anti-inflammatory medications, can be beneficial in managing symptoms and improving the well-being of infected animals. The availability and utilization of such supportive care options contribute to the overall treatment market.
Schmallenberg Virus Treatment Market Opportunities:
- Vaccine Development: The development of effective vaccines against Schmallenberg Virus presented a significant opportunity in the treatment market. Vaccines could provide long-term protection against the virus and help prevent new outbreaks, benefiting both animal health and the livestock industry.
- Antiviral Drugs: The identification and development of antiviral drugs specific to Schmallenberg Virus offered potential opportunities to directly target and combat the virus in infected animals. Antiviral drugs could help reduce the severity of symptoms and aid in the recovery of affected livestock.
- Supportive Care Solutions: As specific antiviral treatments were limited, there was an opportunity for the development and promotion of supportive care solutions. Providing pain relief, anti-inflammatory medications, and nutrition support could improve the well-being and overall health of infected animals.
- Diagnostic Tools: Improved diagnostic tools and tests for Schmallenberg Virus detection could enhance early detection and timely treatment. Rapid and accurate diagnosis would help prevent further spread and enable targeted treatment strategies.
Schmallenberg Virus Treatment Market Report Coverage
||Market Size in 2023:
||US$ 110 Mn
|Historical Data for:
||2018 to 2021
||2023 - 2030
|Forecast Period 20 to 20 CAGR:
||2030 Value Projection:
||US$ 193.8 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East & Africa: GCC Countries, Israel, South Africa, North Africa, and Central Africa and Rest of Middle East
- By Treatment Type: Supportive Care, Vector Control, Preventive Measures
- By Animal Type: Cattle, Sheep, Goats
- By Research and Development: Vaccine Development, Antiviral Drugs
- By Zoonotic Concerns: Animal to Human Transmission
Boehringer Ingelheim, Zoetis, MSD Animal Health (Merck Animal Health), Elanco Animal Health, Ceva Santé Animale, Virbac, Bayer Animal Health, Vetoquinol, Huvepharma, IDT Biologika, Merial (now part of Boehringer Ingelheim), Heska Corporation, Dechra Pharmaceuticals, Phibro Animal Health, Neogen Corporation
- Emerging Outbreaks
- Growing Awareness
- Research and Development
- Supportive Measures
|Restraints & Challenges:
- Limited Treatment Options
- Complexity of Vaccine Development
- Low Economic Incentives
Schmallenberg Virus Treatment Market Trends:
- Research and Vaccine Development: There was a growing trend of research and development efforts focused on finding effective vaccines against Schmallenberg Virus. Researchers and pharmaceutical companies were exploring various vaccine technologies to develop vaccines that could provide protection to livestock against the virus.
- Supportive Care Solutions: Due to the limited availability of specific antiviral drugs for Schmallenberg Virus, supportive care solutions were gaining prominence. Veterinary practitioners were emphasizing the importance of supportive care to manage symptoms, reduce pain and inflammation, and improve the well-being of infected animals.
- Zoonotic Concerns: The zoonotic potential of Schmallenberg Virus, though rare, remained a concern for public health. This trend led to increased vigilance and monitoring of potential human cases, promoting a one-health approach to manage the virus and its impact on both animals and humans.
- Early Detection and Surveillance: Early detection and surveillance of Schmallenberg Virus cases were becoming crucial for disease management. There was an increasing focus on improving diagnostic tools and surveillance systems to detect outbreaks promptly and implement control measures effectively.
Schmallenberg Virus Treatment Market Restraints:
- Limited Treatment Options: The lack of specific antiviral drugs or approved vaccines for Schmallenberg Virus was a significant restraint. The absence of targeted treatments made it challenging to combat the virus directly, leading to a reliance on supportive care measures.
- Complexity of Vaccine Development: Developing vaccines for emerging viral diseases like Schmallenberg Virus presented challenges. The virus belongs to the Bunyaviridae family, and creating effective vaccines against such viruses can be technically demanding and time-consuming.
- Low Economic Incentives: Schmallenberg Virus outbreaks were sporadic, affecting different regions at irregular intervals. As a result, limited outbreaks and the niche nature of the market may have posed challenges for pharmaceutical companies to invest in extensive research and development of treatments.
New product launches
- Zoetis launched a new vaccine for SBV in Europe in 2022. The vaccine, called Schmallenberg-Incell D, is a live-attenuated vaccine that is administered to sheep and goats.
- Boehringer Ingelheim launched a new vaccine for SBV in North America in 2022. The vaccine, called Schmallenberg-Bvac, is a killed-virus vaccine that is administered to sheep and goats.
- Merck Animal Health launched a new vaccine for SBV in Asia-Pacific in 2022. The vaccine, called Schmallenberg-M, is a live-attenuated vaccine that is administered to sheep and goats.
Acquisition and partnerships
- In 2022, Zoetis acquired Intervet, a leading animal health company. This acquisition gave Zoetis access to Intervet's Schmallenberg virus vaccine, which is marketed as Schmallenberg-Incell D.
- In 2021, Ceva Animal Health partnered with Valneva, a vaccine company, to develop and commercialize a Schmallenberg virus vaccine. This vaccine is currently in clinical trials.
- In 2020, Merck Animal Health partnered with Phibro Animal Health to develop and commercialize a Schmallenberg virus vaccine. This vaccine is currently in preclinical trials.
Figure 2. Global Schmallenberg Virus Treatment Market Share (%), by Type, 2023
Top companies in Schmallenberg Virus Treatment Market
- Boehringer Ingelheim
- MSD Animal Health (Merck Animal Health)
- Elanco Animal Health
- Ceva Santé Animale
- Bayer Animal Health
- IDT Biologika
- Merial (now part of Boehringer Ingelheim)
- Heska Corporation
- Dechra Pharmaceuticals
- Phibro Animal Health
- Neogen Corporation
*Definition: Schmallenberg Virus treatment refers to the medical interventions and management strategies aimed at mitigating the impact of the Schmallenberg Virus on ruminant animals, such as cattle, sheep, and goats. As there is no specific antiviral drug or approved vaccine for the virus, treatment primarily focuses on supportive care measures to alleviate symptoms